Roivant Sciences Discovery

Roivant Sciences Discovery is owned by Sumitomo Chemical.

Sumitomo Chemical is one of the...

• Forbes Global 2000 (#1424);
• Nikkei 225;
• Topix.

Sumitomo Chemical is a company listed under the stock ticker 4005 (JP).

Sumitomo Chemical has a direct presence in 6 countries.

Sumitomo Chemical has 27 subsidiaries including Asahi Chemical, Covant Therapeutics and Datavant.

They are in:

• Biotechnology57%
• Chemicals25%
• Other18%

View the org chart displaying its 3 main executives

Most searched biographies at Roivant Sciences Discovery

• Matt Maisak, Chief Operating Officer, Roivant Platforms
• Christopher Winter, Head of Portfolio Strategy
• Eric Valeur, Vice President and Head of Drug Discovery

Create your alert
to follow the executive moves at Roivant Sciences Discovery.

Sumitomo Chemical has 2,293 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Eurofins PSS Insourcing Solutions (United States (USA)).

Popular M&A news in Biotechnology

• N-Power Medicine has just announced a $72 Million fundraising (posted on July 2 2024).
• LB Pharmaceuticals has just announced a $75 Million fundraising (posted on June 28 2024).
• Formation Bio has just announced a $372 Million fundraising (posted on June 27 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Kristina Burow - Director at Scholar Rock
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by Roivant Sciences Discovery

• Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease | Roivant Sciences Ltd.
• Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results | Roivant Sciences Ltd.
• Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million | Roivant Sciences Ltd.
• Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease | Roivant Sciences Ltd.
• Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old | Roivant Sciences Ltd.
• Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old | Roivant Sciences Ltd.
• Press Releases | Roivant Sciences Ltd.
• Events & Presentations | Roivant Sciences Ltd.
• News & Press Releases | Roivant
• View more press releases Close

Social media about Roivant Sciences Discovery

• Roivant Sciences Discovery on Wikipedia, Google News & Yahoo Finance
• Roivant Sciences Discovery on LinkedIn, Twitter & YouTube

Contact by email its executives including Matt Maisak

Call Roivant Sciences Discovery at +41 43...

View the org chart

Register to receive your alert

Report an error